December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
December marks a turning point in computational biology, with Exscientia’s AI-designed oncology candidate advancing to mid-stage trials—reshaping how …
Roche’s PD-L1 inhibitor demonstrates durable response in RET-mutant thyroid cancer, offering a new option for patients with limited …
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
GSK’s long-acting biologic reduces exacerbations and improves lung function in eosinophilic asthma, offering a potential once-yearly treatment option.
Despite high hopes, Roche’s anti-amyloid antibody shows no significant benefit in slowing cognitive decline, prompting reevaluation of Alzheimer’s …
FDA mandates clearer drug ads, Merck expands oncology portfolio, and political shifts raise questions about public health leadership.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Memorial Sloan Kettering researchers uncover how pancreatic cancer cells suppress immune triggers by manipulating genetic elements.
A new research center and FDA-backed diversity mandates aim to reshape clinical trial equity and representation across the …
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
Already a subscriber? Log in